[2-(1-(2'-bromo-4'-methoxybenzenesulfonyl)-5-bromo-1H-indol-3-yloxy)ethyl]dimethylamine | 700838-36-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - Pyrroloazepines
• 英文名称: [2-(1-(2'-bromo-4'-methoxybenzenesulfonyl)-5-bromo-1H-indol-3-yloxy)ethyl]dimethylamine
• 英文别名: 2-[5-bromo-1-(2-bromo-4-methoxyphenyl)sulfonylindol-3-yl]oxy-N,N-dimethylethanamine
• CAS: 700838-36-4
• 化学式: C₁₉H₂₀Br₂N₂O₄S
• 分子量: 532.253
• InChiKey: SRMOZYUGPRUDHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  69.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• N-arylsulfonyl-3-aminoalkoxyindoles
  申请人：Ramakrishna Satya Nirogi Venkata

  公开号：US20060173193A1

  公开（公告）日：2006-08-03

  N-arylsulfonyl-3-aminoalkoxyindoles indole compounds, radioisotopes, stereoisomers, geometric forms, N-oxides, polymorphs and pharmaceutically acceptable salts.

  N-芳基磺酰基-3-氨基烷氧基吲哚类化合物，包括吲哚衍生物、放射性同位素、立体异构体、几何异构体、N-氧化物、多晶形和药学上可接受的盐。
• N-ARYLSULFONYL-3-AMINOALKOXYINDOLES
  申请人：Suven Life Sciences Limited

  公开号：EP1567492B1

  公开（公告）日：2013-05-22
• US7507835B2
  申请人：——

  公开号：US7507835B2

  公开（公告）日：2009-03-24
• US7718690B2
  申请人：——

  公开号：US7718690B2

  公开（公告）日：2010-05-18
• [EN] N-ARYLSULFONYL-3-AMINOALKOXYINDOLES<br/>[FR] N-ARYLSULFONYL-3-AMINOALKOXYINDOLES
  申请人：SUVEN LIFE SCIENCES LTD

  公开号：WO2004048328A2

  公开（公告）日：2004-06-10

  The present invention describes substituted 3-Aminoalkoxyindoles, compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and any suitable combination of the above. The invention also discloses the processes for preparing such compounds of the general formula (I), its stereoisomers, its radioisotopes, its geometric forms, its N-oxides, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, its useful bio-active metabolites and also includes any suitable combination of the above. Further described are various methods of administering these compounds of general formula (I), i.e. pharmaceutically acceptable dosage forms, their composition and their use in either therapy or diagnosis.